The authors further established a reduction in the viability of pancreatic cancer cell lines by application of a dual-acting agent using the PI3K inhibitor, ZSTK474, and the Raf/MEK inhibitor, RO5126766 (Van Dort et al., 2015). This evidence concerns the gene PIK3CA and pancreatic neoplasm.